πŸ‡ΊπŸ‡Έ FDA
Patent

US 10287606

Genomic engineering of pluripotent cells

granted A61KA61K2035/124A61K2239/31

Quick answer

US patent 10287606 (Genomic engineering of pluripotent cells) held by Fate Therapeutics, Inc. expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2035/124, A61K2239/31, A61K2239/38, A61K40/10